Bristol Myers Squibb announced failure of Reblozyl to meet the primary endpoint in the Phase III INDEPENDENCE trial for anemia associated with myelofibrosis, showing no significant reduction in transfusion dependence. Despite this, the company reported some clinically meaningful secondary outcomes and plans to engage with regulators on potential submissions. The drug, a recombinant fusion protein targeting red blood cell maturation, remains an option in other approved indications. Analysts highlight the ongoing unmet need for effective myelofibrosis anemia treatments following this setback.